Mechanisms and consequences of fibrosis in systemic sclerosis
- 1 March 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 2 (3), 134-144
- https://doi.org/10.1038/ncprheum0115
Abstract
Systemic sclerosis (SSc), also known as scleroderma, is a complex connective tissue disease that is associated with a high mortality and is challenging to treat because of its clinical heterogeneity and a lack of effective antifibrotic therapies. SSc has vascular, immunologic and fibrotic components that are pathologically interconnected. A growing understanding of the molecular and cellular mechanisms that underlie SSc pathogenesis provides logical and novel approaches to treatment. At present most therapies are organ-based. Vascular and inflammatory components of the disease can also be treated, but effective antifibrotic therapies are lacking. A number of key molecular mediators have the potential to alter immune-cell, vascular and fibrotic processes and these mediators, which include transforming growth factor-beta isoforms, endothelin-1, connective-tissue growth factor, chemokines and members of the interleukin family, are attractive targets for therapeutic modulation. Key mediators can be blocked using antibodies, soluble receptors, endogenous inhibitors or small-molecule antagonists of ligands, receptors or signaling intermediates. Overall, this is an exciting time for new therapies in SSc and advances are being made in synchrony with an improved understanding of the molecular and biochemical basis of the disease.Keywords
This publication has 50 references indexed in Scilit:
- Paclitaxel Modulates TGFβ Signaling in Scleroderma Skin Grafts in Immunodeficient MicePLoS Medicine, 2005
- Constitutive Phosphorylation of Focal Adhesion Kinase Is Involved in the Myofibroblast Differentiation of Scleroderma FibroblastsJournal of Investigative Dermatology, 2005
- Direct binding of anti–DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosisArthritis & Rheumatism, 2004
- Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosisArthritis & Rheumatism, 2004
- Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosisArthritis & Rheumatism, 2003
- Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight‐skin mouseArthritis & Rheumatism, 2003
- Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblastsArthritis & Rheumatism, 2003
- Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesisCurrent Opinion in Rheumatology, 2001
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Relaxor-like and spectroscopic properties of niobium modified barium titanateZeitschrift für Physik B Condensed Matter, 2000